Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2-Breast Cancer

被引：2
|
作者：
Chang, Jenny C. [1 ]
O'Regan, Ruth [2 ,3 ,4 ]
机构：
[1] Houston Methodist Canc Ctr, Houston, TX 77030 USA
[2] Univ Wisconsin, Sch Med & Publ Hlth, Med, Madison, WI 53706 USA
[3] Carbone Canc Ctr, Hematololgy Oncol Div, Madison, WI USA
[4] Carbone Canc Ctr, Clin Res, Madison, WI USA
来源：
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2018年 / 16卷
关键词：
METASTATIC BREAST-CANCER; 4/6 INHIBITOR PALBOCICLIB; RANDOMIZED PHASE-II; FULVESTRANT; 500; MG; ANASTROZOLE; ENDOCRINE THERAPY; DOUBLE-BLIND; AROMATASE INHIBITORS; ESR1; MUTATIONS; 1ST-LINE TREATMENT;
D O I：
10.6004/jnccn.2018.0200
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Endocrine therapy remains the backbone for treatment of hormone receptor-positive breast cancer in the metastatic setting. Despite the effectiveness of endocrine therapy, primary and acquired endocrine resistance continue to be important clinical challenges. The landscape of metastatic breast cancer treatment has changed considerably with the incorporation of novel agents, including cyclin-dependent kinase 4/6 and mammalian target of rapamycin inhibitors. This article reviews current endocrine treatment strategies and recent and ongoing studies of combination therapies in metastatic hormone receptor-positive, HER2-negative breast cancer.
引用
收藏
页码：S1 / S14
页数：14
相关论文
共 50 条
  • [1] Everolimus-based combination therapies for HR+, HER2-metastatic breast cancer
    O'Shaughnessy, Joyce
    Beck, J. Thaddeus
    Royce, Melanie
    CANCER TREATMENT REVIEWS, 2018, 69 : 204 - 214
  • [2] Optimizing CDK4/6 inhibitors in advanced HR+/HER2-breast cancer: A personalized approach
    Fontanella, Caterina
    Giorgi, Carlo Alberto
    Russo, Stefania
    Angelini, Silvia
    Nicolardi, Linda
    Giarratano, Tommaso
    Frezzini, Simona
    Pestrin, Marta
    Palleschi, Dario
    Bolzonello, Silvia
    Parolin, Veronica
    Haspinger, Eva R.
    De Rossi, Costanza
    Greco, Filippo
    Gerratana, Lorenzo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 180
  • [3] Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2-breast cancer
    Martinez-Perez, Carlos
    Turnbull, Arran K.
    Kay, Charlene
    Dixon, J. Michael
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (01) : 67 - 86
  • [4] HR+/HER2-Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
    Jerzak, Katarzyna J.
    Bouganim, Nathaniel
    Brezden-Masley, Christine
    Edwards, Scott
    Gelmon, Karen
    Henning, Jan-Willem
    Hilton, John F.
    Sehdev, Sandeep
    CURRENT ONCOLOGY, 2023, 30 (06) : 5425 - 5447
  • [5] Controversial topics in metastatic HR+/HER2-breast cancer: Guiding treatment by a modified Delphi approach
    Fabi, Alessandra
    Buono, Giuseppe
    Bria, Emilio
    Bianchini, Giampaolo
    Curigliano, Giuseppe
    De Laurentiis, Michelino
    De Placido, Sabino
    Del Mastro, Lucia
    Guarneri, Valentina
    Generali, Daniele
    Livi, Lorenzo
    Lorusso, Vito
    Montemurro, Filippo
    Puglisi, Fabio
    Vigneri, Paolo
    Zambelli, Alberto
    Arpino, Grazia
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] CDK4/6 inhibitors in advanced HR+/HER2-breast cancer - a multicenter real world data analysis
    Mueller, C.
    Kiver, V
    Solomayer, E-F
    Wagenpfeil, G.
    Neeb, C.
    Blohmer, J. U.
    Abramian, A., V
    Maass, N.
    Schuetz, F.
    Kolberg-Liedtke, C.
    Ralser, D. J.
    Rambow, A-C
    BREAST CARE, 2023, 18 (01) : 31 - 41
  • [7] Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2-Advanced or Metastatic Breast Cancer
    Qureshi, Zaheer
    Jamil, Abdur
    Fatima, Eeshal
    Altaf, Faryal
    Siddique, Rimsha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (01): : 6 - 15
  • [8] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
  • [9] Treatment of HR+/HER2-breast cancer in urban mainland China: results from the CancerMPact Survey 2019
    Murali, Bhavna
    Durbin, Laura
    Vijaykumar, Sapna
    Yang, Linda
    Li, Song
    Zhao, Linda
    Hawthorne, Stephanie
    Kanas, Gena
    Davis, Christine
    Clark, Otavio
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 195 (03) : 441 - 451
  • [10] Evolving perspectives on the treatment of HR+/HER2+metastatic breast cancer
    Pegram, Mark
    Pietras, Richard
    Dang, Chau T.
    Murthy, Rashmi
    Bachelot, Thomas
    Janni, Wolfgang
    Sharma, Priyanka
    Hamilton, Erika
    Saura, Cristina
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
12345